XML 36 R20.htm IDEA: XBRL DOCUMENT v3.24.2
Business and Products Information
6 Months Ended
Jun. 30, 2024
Segment Reporting [Abstract]  
Business and Products Information Business and Products Information
We conduct our business in one operating and reportable segment that provides our medical device products to healthcare providers and patients globally with manufacturing facilities in the United States and Mexico.
Avanos develops, manufactures and markets its recognized brands globally and holds leading market positions in multiple categories across its portfolio. Our management evaluates net sales by product category within our single reportable segment as follows (in millions):
Three Months Ended June 30,Six Months Ended June 30,
2024202320242023
Digestive Health$97.7 $93.0 $192.4 $181.8 
Pain Management and Recovery:
Surgical pain and recovery32.3 34.8 63.5 69.5 
Interventional pain41.7 41.6 81.9 77.4 
Total Pain Management and Recovery74.0 76.4 145.4 146.9 
Total Net Sales$171.7 $169.4 $337.8 $328.7 
Digestive Health is a portfolio of products such as our MIC-KEY enteral feeding tubes, Corpak patient feeding solutions and NeoMed neonatal and pediatric feeding solutions.
Pain Management and Recovery is a portfolio of products including:
Surgical pain and recovery products such as ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems; and
Interventional pain solutions, which provide minimally invasive pain relief therapies, such as our COOLIEF pain therapy, OrthogenRx’s knee osteoarthritis HA pain relief injection products and Diros’ RFA products used to treat chronic pain conditions.
Liabilities for estimated returns, rebates and incentives are presented in the table below (in millions):
June 30, 2024December 31, 2023
Accrued rebates$12.6 $10.4 
Accrued customer incentives9.2 7.3 
Accrued rebates and customer incentives21.8 17.7 
Accrued sales returns(a)
0.1 0.1 
Total estimated liabilities$21.9 $17.8 
__________________________________________________
(a)Accrued sales returns are included in “Other” in the accrued expenses table in Note 5, “Supplemental Balance Sheet Information”.
Due to the nature of our business, we receive purchase orders for products under supply agreements which are normally fulfilled within three to four weeks. Our performance obligations under purchase orders are satisfied and revenue is recognized at a point in time, which is upon shipment or upon delivery of our products, depending on shipping terms. Accordingly, we normally do not have transactions that give rise to material unfulfilled performance obligations.